Clarus Therapeutics Statistics
Share Statistics
Clarus Therapeutics has 0
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -1.03 and the forward
PE ratio is null.
Clarus Therapeutics's PEG ratio is
0.
| PE Ratio | -1.03 |
| Forward PE | n/a |
| PS Ratio | 4.18 |
| Forward PS | n/a |
| PB Ratio | -3.67 |
| P/FCF Ratio | -1.33 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Clarus Therapeutics has an Enterprise Value (EV) of 74.24M.
| EV / Sales | 5.32 |
| EV / EBITDA | -1.87 |
| EV / EBIT | -1.7 |
| EV / FCF | -1.69 |
Financial Position
The company has a current ratio of 0.78,
with a Debt / Equity ratio of -2.66.
| Current Ratio | 0.78 |
| Quick Ratio | 0.57 |
| Debt / Equity | -2.66 |
| Debt / EBITDA | -1.06 |
| Debt / FCF | -0.96 |
| Interest Coverage | -1.56 |
Financial Efficiency
Return on Equity is 355% and Return on Invested Capital is -130.54%.
| Return on Equity | 355% |
| Return on Assets | -109.29% |
| Return on Invested Capital | -130.54% |
| Revenue Per Employee | $872,312.5 |
| Profits Per Employee | $-3,532,000 |
| Employee Count | 16 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 0.19 |
Taxes
| Income Tax | 15.89M |
| Effective Tax Rate | -39.13% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is 0, so Clarus Therapeutics's
price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.29 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 22.28 |
| Average Volume (20 Days) | n/a |
Income Statement
In the last 12 months, Clarus Therapeutics had revenue of 13.96M
and earned -56.51M
in profits. Earnings per share was -2.35.
| Revenue | 13.96M |
| Gross Profit | 11.24M |
| Operating Income | -24.72M |
| Net Income | -56.51M |
| EBITDA | -39.73M |
| EBIT | -24.72M |
| Earnings Per Share (EPS) | -2.35 |
Full Income StatementBalance Sheet
The company has 26.41M in cash and 42.27M in
debt, giving a net cash position of -15.85M.
| Cash & Cash Equivalents | 26.41M |
| Total Debt | 42.27M |
| Net Cash | -15.85M |
| Retained Earnings | -321.65M |
| Total Assets | n/a |
| Working Capital | n/a |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -43.79M
and capital expenditures -25K, giving a free cash flow of -43.81M.
| Operating Cash Flow | -43.79M |
| Capital Expenditures | -25K |
| Free Cash Flow | -43.81M |
| FCF Per Share | -1.82 |
Full Cash Flow StatementMargins
Gross margin is 80.51%, with operating and profit margins of -177.13% and -404.9%.
| Gross Margin | 80.51% |
| Operating Margin | -177.13% |
| Pretax Margin | -291.02% |
| Profit Margin | -404.9% |
| EBITDA Margin | -284.67% |
| EBIT Margin | -177.13% |
| FCF Margin | -313.9% |
